Robinson Alternative Yield Pre-Merger SPAC ETF (SPAX) to Close
The ETF will cease trading on NYSE Arca at the close of regular trading on April 7, 2025 (the 'Closing Date'). It will no longer accept purchase orders as of that date.
Shareholders may sell their holdings in the fund prior to the Closing Date through standard brokerage transactions, which may incur customary brokerage charges. After April 7, 2025, shareholders may only sell shares to select broker-dealers, with no assurance of an active market during this period.
Between April 7, 2025 and April 11, 2025 (the 'Liquidation Date'), SPAX will liquidate its portfolio, increasing its cash holdings, which will result in portfolio holdings deviating from the fund's stated investment objectives.
On or around the Liquidation Date, SPAX will distribute its remaining assets as cash pro rata to shareholders of record who have not sold or redeemed their shares. This distribution will generally be treated as a taxable event, and shareholders should consult their tax advisers to understand the implications of capital gains or losses. Additionally, the liquidation may include accrued capital gains and dividends. After these distributions, the fund will officially terminate.
About Tidal Financial Group
Formed by ETF industry pioneers and thought leaders, Tidal Investments LLC is dedicated to revolutionizing ETF development, launch, marketing, and sales. With a focus on growing AUM, Tidal provides a comprehensive suite of services, proprietary tools, and methodologies designed to bring lasting investment ideas to market. Tidal is committed to ETF innovation, equipping issuers with the intelligence and tools needed to efficiently launch ETFs and optimize growth potential in a highly competitive space. For more information, visit https://www.tidalfinancialgroup.com.
CONTACT: For further inquiries, please contact Gavin Filmore at gfilmore@tidalfg.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Navatar Unveils AI-Powered CRM That Meets Dealmakers Where They Work From Outlook to Slack to CRM: Private Equity's First Truly Embedded Intelligence Platform For Salesforce
By GlobeNewswire Published on July 23, 2025, 10:30 IST LONDON and NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) — Navatar, the leading cloud platform for private equity and investment banking, today announced the launch of its next-generation, fully AI-powered CRM. Designed to meet the fast-evolving needs of private capital markets, the new Navatar platform combines intelligence, automation, and usability—solving one of the biggest challenges firms face when trying to put AI to work: data. In a recent Harvard Business Review article, 'How Private Equity Firms Are Creating Value with AI', highlighting the industry's rapid embrace of artificial intelligence – from identifying targets to improving portfolio performance – the authors note a common bottleneck: without structured, usable data, AI tools can't deliver their full potential. 'Everyone wants to use AI, but few have the data to make it work,' said Alok Misra, CEO of Navatar. 'That's because most CRMs are still clunky, inflexible systems that require painful manual data entry. We built the new Navatar platform to break that cycle.' A Media Snippet accompanying this announcement is available by clicking on this link. Navatar automatically captures relevant information from Outlook, LinkedIn, Slack, call notes, documents and third-party data—turning your team's daily activity into structured, usable intelligence for AI to operate on. No more chasing team members to update fields or fill out forms. While many firms invested in legacy, highly customized CRMs, they've found themselves stuck: the systems are slow to change, hard to use, and often ignored by the very people driving deals. Navatar flips that experience on its head—offering: Built-in automation to eliminate manual data entry Automated multi-tagging for people, companies, deals and more Embedded AI across sourcing, diligence, fundraising, and portfolio management Fast time-to-value without the need for costly customization A modern user experience that keeps deal teams coming back AI Where You Work: Inside Outlook, Navatar or Slack Navatar combines the best of Salesforce AI (Agentforce 3) and Microsoft Copilot so dealmakers no longer need to log into a CRM to get intelligence. Whether working inside Outlook, Navatar or Slack, users receive real-time insights, recommendations, and automation—all natively delivered in the tools they already use. Within Microsoft Outlook Smart Relationship Insights : Get a 360° view of any contact—who knows them internally, recent interactions, open deals, and more—directly inside your inbox. : Get a 360° view of any contact—who knows them internally, recent interactions, open deals, and more—directly inside your inbox. Email Summarization & Action Suggestions : AI summarizes long email threads and suggests follow-ups, tasks, and next steps. : AI summarizes long email threads and suggests follow-ups, tasks, and next steps. Deal Context at Your Fingertips : See associated deals, stages, and pipeline status without leaving Outlook. : See associated deals, stages, and pipeline status without leaving Outlook. Automated Meeting Prep : Copilot briefs you before a meeting by pulling intelligence from emails, calendar invites, past notes, and CRM activity. : Copilot briefs you before a meeting by pulling intelligence from emails, calendar invites, past notes, and CRM activity. Task & Data Capture: Turn meeting notes and emails into structured CRM entries automatically—no copy-pasting. Within Navatar Thematic Deal Sourcing : Surface emerging trends and high-fit targets based on proprietary and third-party data analysis. : Surface emerging trends and high-fit targets based on proprietary and third-party data analysis. Predictive Scoring : Rank inbound deals or prospects by likelihood to convert, based on past behavior and firm strategy. : Rank inbound deals or prospects by likelihood to convert, based on past behavior and firm strategy. Relationship Intelligence : Auto-map referral paths, warm intros, and deal team connectivity using AI across your team's network. : Auto-map referral paths, warm intros, and deal team connectivity using AI across your team's network. Document Intelligence : Use natural language processing to extract key terms, risks, and summaries from CIMs, pitch decks, and earnings calls. : Use natural language processing to extract key terms, risks, and summaries from CIMs, pitch decks, and earnings calls. Pipeline Management : AI generated deal summaries for easy pipeline reporting. : AI generated deal summaries for easy pipeline reporting. Automated Task Management : AI creates tasks, follow-ups based on triggers. : AI creates tasks, follow-ups based on triggers. Portfolio Alerts : Get AI-generated notifications on portfolio company performance shifts or risk flags. : Get AI-generated notifications on portfolio company performance shifts or risk flags. Fundraising & LP Intelligence: Personalize LP communications, score investor engagement, and automate routine updates. Within Slack CRM Alerts in Slack: Receive pipeline updates, LP activity alerts, and portfolio company notifications directly in relevant Slack channels. Receive pipeline updates, LP activity alerts, and portfolio company notifications directly in relevant Slack channels. Conversation-to-CRM Linkage: Slack messages can be tagged and associated with deals, contacts, or tasks inside Navatar, making it easy to capture institutional knowledge. Slack messages can be tagged and associated with deals, contacts, or tasks inside Navatar, making it easy to capture institutional knowledge. AI Summaries & Actions: AI monitors key deal-related channels and suggests follow-ups, summaries, or actions. AI monitors key deal-related channels and suggests follow-ups, summaries, or actions. Frictionless Collaboration: Deal teams can share notes, escalate issues, or push tasks to CRM—all from Slack. 'We're not just embedding AI into a CRM—we're embedding it into the workflow,' said Misra. 'Whether you're in Outlook, Slack, or Navatar itself, the intelligence meets you where you are.' For more information on Navatar for Private Equity, please visit: Private Equity CRM About Navatar Navatar (@navatargroup), the CRM platform for alternative assets and investment banking firms, is a low-touch, high-impact intelligence engine purpose-built for private markets. Now fully AI-powered, Navatar captures intelligence automatically and delivers insights directly into Outlook, Slack, and CRM—transforming routine activity into firmwide intelligence. Built on Salesforce and integrated with Microsoft Copilot, the platform eliminates manual data entry, unifies deal and relationship context, and orchestrates complex workflows without disrupting how investment professionals work. Backed by over two decades of CRM expertise, Navatar is used by hundreds of global firms to drive institutional knowledge, gain early access to opportunities, and execute smarter, faster. For more information, visit TeamNavatar [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hamilton Spectator
6 hours ago
- Hamilton Spectator
50-Day Countdown to the 2025 CIFTIS Starts
BEIJING, July 23, 2025 (GLOBE NEWSWIRE) — The 2025 China International Fair for Trade in Services (CIFTIS) will be held from September 10 to 14 at Shougang Park in Beijing, with a 50-day countdown starting today. As a key global platform for exchange and cooperation in the field of trade in services, the upcoming CIFTIS will continue to deepen international collaboration, gather global insights, and showcase the latest achievements and emerging trends in the sector — injecting fresh momentum into the recovery and growth of the world economy. A Media Snippet accompanying this announcement is available by clicking on this link. Source: CIFTIS
Hamilton Spectator
10 hours ago
- Hamilton Spectator
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering will not be subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering as more specifically described in the Offering Document and for gout programs, general corporate and working capital purposes. In connection with the Offering, the Company paid an aggregate of $12,264 in finder's fees and issued, in aggregate, 16,800 finder's warrants. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The issuance of 8,191 Units to an insider of the Company constitutes a 'related party transaction' as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ('MI 61-101'). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company relied on exemptions from the formal valuation and minority shareholder approval requirements, respectively, as neither the fair market value of the Units nor the consideration for such Units, insofar as it involves the insider, exceeds 25 percent of the Company's market capitalization. In other news, the non-brokered private placement that was announced on May 19, 2025 will not proceed. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at . For more information, please contact: Forward-Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on . Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
